|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,788,000 |
Market
Cap: |
1.92(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$14.19 - $52.31 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Arvinas is a biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins. Co. is developing ARV-110, a proteolysis targeting chimeras (PROTAC) targeted protein degrader targeting the androgen receptor protein for the treatment of men with metastatic castration-resistant prostate cancer. Co. is also developing ARV-471, a PROTAC targeted protein degrader targeting the estrogen receptor protein, or ER, for the treatment of patients with locally advanced or metastatic ER positive / HER2 negative breast cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
10,298 |
11,622 |
21,554 |
Total Sell Value |
$0 |
$484,521 |
$516,810 |
$859,747 |
Total People Sold |
0 |
4 |
4 |
4 |
Total Sell Transactions |
0 |
4 |
5 |
9 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Morrison Briggs |
Director |
|
2022-04-14 |
4 |
AS |
$65.24 |
$1,392,616 |
D/D |
(20,960) |
19,976 |
|
-30% |
|
Morrison Briggs |
Director |
|
2022-04-14 |
4 |
OE |
$16.00 |
$259,008 |
D/D |
16,188 |
40,936 |
|
- |
|
Taylor Ian |
Chief Scientific Officer |
|
2022-03-31 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
80,962 |
|
- |
|
Cassidy Sean A |
Chief Financial Officer |
|
2022-03-11 |
4 |
AS |
$70.00 |
$1,050,000 |
D/D |
(15,000) |
161,447 |
|
-20% |
|
Cassidy Sean A |
Chief Financial Officer |
|
2022-03-11 |
4 |
OE |
$16.00 |
$240,000 |
D/D |
15,000 |
176,447 |
|
- |
|
Houston John G |
President and CEO |
|
2022-03-04 |
4 |
S |
$63.94 |
$385,175 |
D/D |
(6,024) |
843,820 |
|
24% |
|
Houston John G |
President and CEO |
|
2022-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,511 |
849,844 |
|
- |
|
Cassidy Sean A |
Chief Financial Officer |
|
2022-03-04 |
4 |
S |
$63.94 |
$101,856 |
D/D |
(1,593) |
161,447 |
|
24% |
|
Cassidy Sean A |
Chief Financial Officer |
|
2022-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,791 |
163,040 |
|
- |
|
Taylor Ian |
Chief Scientific Officer |
|
2022-03-04 |
4 |
S |
$63.94 |
$55,564 |
D/D |
(869) |
83,962 |
|
24% |
|
Taylor Ian |
Chief Scientific Officer |
|
2022-03-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,686 |
84,831 |
|
- |
|
Taylor Ian |
Chief Scientific Officer |
|
2022-03-01 |
4 |
OE |
$16.00 |
$56,000 |
D/D |
3,500 |
82,145 |
|
- |
|
Taylor Ian |
Chief Scientific Officer |
|
2022-02-15 |
4 |
AS |
$71.74 |
$1,460,316 |
D/D |
(20,000) |
78,645 |
|
-38% |
|
Taylor Ian |
Chief Scientific Officer |
|
2022-02-15 |
4 |
OE |
$19.36 |
$387,200 |
D/D |
20,000 |
98,645 |
|
- |
|
Morrison Briggs |
Director |
|
2022-01-14 |
4 |
AS |
$64.33 |
$1,374,021 |
D/D |
(20,960) |
24,748 |
|
-37% |
|
Morrison Briggs |
Director |
|
2022-01-14 |
4 |
OE |
$16.00 |
$259,008 |
D/D |
16,188 |
45,708 |
|
- |
|
Peck Ronald |
Chief Medical Officer |
|
2021-12-30 |
4 |
AS |
$80.35 |
$1,612,264 |
D/D |
(20,000) |
5,402 |
|
-47% |
|
Peck Ronald |
Chief Medical Officer |
|
2021-12-30 |
4 |
OE |
$26.58 |
$830,600 |
D/D |
20,000 |
25,402 |
|
- |
|
Cassidy Sean A |
Chief Financial Officer |
|
2021-12-17 |
4 |
AS |
$70.00 |
$1,050,000 |
D/D |
(15,000) |
158,249 |
|
-25% |
|
Cassidy Sean A |
Chief Financial Officer |
|
2021-12-17 |
4 |
OE |
$16.00 |
$240,000 |
D/D |
15,000 |
173,249 |
|
- |
|
Ratcliffe Liam |
Director |
|
2021-12-16 |
4 |
S |
$68.97 |
$5,944,418 |
I/I |
(85,705) |
185,686 |
|
18% |
|
Ratcliffe Liam |
Director |
|
2021-12-15 |
4 |
S |
$65.74 |
$7,584,964 |
I/I |
(113,536) |
271,391 |
|
17% |
|
Ratcliffe Liam |
Director |
|
2021-12-14 |
4 |
S |
$64.20 |
$10,303,999 |
I/I |
(156,464) |
384,927 |
|
11% |
|
Taylor Ian |
Chief Scientific Officer |
|
2021-11-15 |
4 |
AS |
$83.07 |
$1,680,746 |
D/D |
(20,000) |
78,645 |
|
-19% |
|
Taylor Ian |
Chief Scientific Officer |
|
2021-11-15 |
4 |
OE |
$16.00 |
$346,188 |
D/D |
20,000 |
98,645 |
|
- |
|
174 Records found
|
|
Page 2 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|